# RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial

> **NCT01127542** · PHASE2 · TERMINATED · sponsor: **The Christie NHS Foundation Trust** · enrollment: 1 (actual)

## Conditions studied

- Chronic Lymphocytic Leukaemia

## Interventions

- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01127542
- **Lead sponsor:** The Christie NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-05
- **Primary completion:** —
- **Final completion:** 2011-12
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Potential safety issue of second primary malignancies in patients treated with lenalidomide.
- **Last updated:** 2011-12-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01127542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01127542, "RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT01127542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*